# Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.

> **NCT01854372** · PHASE2 · WITHDRAWN · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Intermediate (Burkitt-Like) Lymphoma

## Interventions

- **DRUG:** R-HCVAD and R-MC

## Key facts

- **NCT ID:** NCT01854372
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854372, "Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01854372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*